{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:59:17Z","timestamp":1776725957192,"version":"3.51.2"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["British Journal of Plastic Surgery"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.bjps.2004.12.007","type":"journal-article","created":{"date-parts":[[2005,4,2]],"date-time":"2005-04-02T12:14:54Z","timestamp":1112444094000},"page":"504-510","source":"Crossref","is-referenced-by-count":53,"title":["Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report"],"prefix":"10.1016","volume":"58","author":[{"given":"M.","family":"Lissia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Figus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjps.2004.12.007_bib1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption rembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bjps.2004.12.007_bib3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70196-0","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Wolkenstein","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.bjps.2004.12.007_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2004.12.007_bib5","series-title":"Total burn care","first-page":"432","article-title":"Exfoliative and necrotizing conditions of the integument","author":"Hollyoak","year":"1996"},{"key":"10.1016\/j.bjps.2004.12.007_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ageing\/22.6.450","article-title":"Toxic epidermal necrolysis (Lyell's syndrome) in 77 elderly patients","volume":"22","author":"Bastuji-Garin","year":"1993","journal-title":"Age Ageing"},{"key":"10.1016\/j.bjps.2004.12.007_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004630-200103000-00009","article-title":"Toxic epidermal necrolysis (TEN) in elderly patients","volume":"22","author":"Honari","year":"2001","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2004.12.007_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib9","first-page":"340","article-title":"Toxic epidermal necrolysis: a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids","volume":"180","author":"Herndon","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.bjps.2004.12.007_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000233856","article-title":"Lymphocyte transformation test in drug-induced toxic epidermal necrolysis","volume":"78","author":"Roujeau","year":"1985","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.bjps.2004.12.007_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00004630-199711000-00009","article-title":"Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage","volume":"18","author":"Engelhardt","year":"1997","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2004.12.007_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004630-199601000-00008","article-title":"Experience with toxic epidermal necrolysis treated in a burn center","volume":"17","author":"Yarbrough","year":"1996","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2004.12.007_bib14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809020-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2004.12.007_bib15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00004630-200021030-00010","article-title":"Drug-induced linear immunoglobulin a bullous disease that clinically mimics toxic epidermal necrolysis","volume":"21","author":"Mofid","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2004.12.007_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/00006534-200209010-00008","article-title":"Outcome of patients with toxic epidermal necrolysis revisited","volume":"110","author":"Ducic","year":"2002","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.bjps.2004.12.007_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous Immunoglobulin treatment for Steven\u2013Johnson syndrome and toxic epidrmal necrolysis","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib21","first-page":"352","article-title":"The estimation of areas of burns","volume":"79","author":"Lund","year":"1944","journal-title":"Surg Gynecol Obstet"},{"key":"10.1016\/j.bjps.2004.12.007_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.bjps.2004.12.007_bib24","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens\u2013Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.bjps.2004.12.007_bib25","doi-asserted-by":"crossref","first-page":"16183","DOI":"10.1074\/jbc.M212188200","article-title":"Intracelleular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bjps.2004.12.007_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with Cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.bjps.2004.12.007_bib27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","article-title":"Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine","volume":"136","author":"Redondo","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib29","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in toxic epidermal necrolysis","volume":"89","author":"Frangogiannis","year":"1996","journal-title":"South Med J"},{"key":"10.1016\/j.bjps.2004.12.007_bib30","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke","year":"1999","journal-title":"Int Care Med"},{"key":"10.1016\/j.bjps.2004.12.007_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.bjps.2004.12.007_bib32","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanbroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib34","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.bjps.2004.12.007_bib36","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bjps.2004.12.007_bib37","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0305-4179(01)00005-5","article-title":"Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins","volume":"27","author":"Paquet","year":"2001","journal-title":"Burns"},{"key":"10.1016\/j.bjps.2004.12.007_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1440-0960.1999.00347.x","article-title":"Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin","volume":"40","author":"Phan","year":"1999","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.bjps.2004.12.007_bib40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00130832-200308000-00006","article-title":"Intravenous immunoglobulins in the treatment of severe drug eruptions","volume":"3","author":"Bachot","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.bjps.2004.12.007_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.bjps.2004.12.007_bib42","first-page":"145","article-title":"Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin","volume":"10","author":"Paquet","year":"2002","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bjps.2004.12.007_bib43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000069961","article-title":"Factor-XIIIa-Positive dendrocytes in drug-induced toxic epidermal necrolysis (Lyel's syndrome): paradoxical activation in skin and rarefaction in lymph nodes","volume":"206","author":"Paquet","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.bjps.2004.12.007_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archderm.138.1.29","article-title":"Solubile interleukin 2 receptor and interleukin 1 alpha in toxic epidermal necrolysis: a comparative analysis of serum and blisters fluid samples","volume":"138","author":"Correia","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000051751","article-title":"CD8+lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host-disease: further similarities with toxic epidermal necrolysis","volume":"203","author":"Correia","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.bjps.2004.12.007_bib48","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archderm.1991.01680050095011","article-title":"T-cell subset in drug- induced toxic epidermal necrolysis: possible pathogenic mechanism induced by CD8-positive T cells","volume":"127","author":"Miyauchi","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib50","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/349796a0","article-title":"Elam-1 is an adhesion molecule for the skin homing T-cells","volume":"349","author":"Picker","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bjps.2004.12.007_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1081-1206(10)62065-0","article-title":"Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin","volume":"91","author":"Mayorga","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.bjps.2004.12.007_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alfa in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.iy.10.040192.001411","article-title":"Apoptosis and programmed cell death in immunity","volume":"10","author":"Cohen","year":"1992","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.bjps.2004.12.007_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0091-6749(00)90191-X","article-title":"Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response","volume":"105","author":"Leyva","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bjps.2004.12.007_bib55","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1097\/00003246-200211000-00029","article-title":"Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's Syndrome) after putative beta-lactam cross-reactivity: case report and scrutiny of antibiotic imputability","volume":"30","author":"Paquet","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bjps.2004.12.007_bib56","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.bjps.2004.12.007_bib57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004630-199709000-00008","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Murphy","year":"1997","journal-title":"J Burn Care Rehabil"}],"container-title":["British Journal of Plastic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007122604003741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007122604003741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T16:39:32Z","timestamp":1586191172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007122604003741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0007122604003741"],"URL":"https:\/\/doi.org\/10.1016\/j.bjps.2004.12.007","relation":{},"ISSN":["0007-1226"],"issn-type":[{"value":"0007-1226","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}